Karyopharm Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Karyopharm Therapeutics Inc KPTI.OQ reported a quarterly adjusted loss of $4.32​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $2.25. The mean expectation of seven analysts for the quarter was for a loss of $4.10 per share. Wall Street expected results to range from $-4.95 to $-3.47 per share.

• Revenue fell 11.4% to $37.93 million from a year ago; analysts expected $36.94 million.

• Karyopharm Therapeutics Inc's reported EPS for the quarter was a loss of $4.32​.

• The company reported a quarterly loss of $37.25 million.

• Karyopharm Therapeutics Inc shares had fallen by 8.6% this quarter and lost 61.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 73.7% above its last closing price of $3.94

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)